论文部分内容阅读
目的:探讨消癌平注射液联合多西他赛+奥沙利铂二线治疗晚期胃癌的有效性及安全性。方法:选取一线使用氟尿嘧啶类为基础化疗失败的晚期胃癌患者84例作为研究对象。随机分为观察组和对照组,每组均为42例。观察组给予消癌平注射液联合多西他赛+奥沙利铂化疗方案,对照组单纯给予多西他赛+奥沙利铂化疗方案,21 d为一个治疗周期,连续治疗2~6个周期。观察2组患者的临床疗效、KPS评分及不良反应。结果:观察组和对照组患者的有效率分别为35.00%和14.63%,观察组患者的有效率显著高于对照组(P<0.05),疾病控制率为77.50%,高于对照组。观察组和对照组患者的中位PFS分别为6.3个月和5.4个月,观察组患者的中位PFS显著高于对照组(P<0.05),观察组患者的中位OS为9.6个月,高于对照组。观察组患者KPS评分改善率为57.50%,显著高于对照组(P<0.05)。观察组患者中性粒细胞减少,白细胞减少,血小板减少和恶心呕吐的发生率显著低于对照组(P<0.05)。结论:消癌平注射液联合多西他赛+奥沙利铂化疗方案治疗晚期胃癌患者,可显著提高临床疗效,延长患者生存期,改善患者生活质量,降低化疗引起的毒副反应,使患者临床获益。
Objective: To investigate the efficacy and safety of Xiao-Jin-Ping injection combined with docetaxel plus oxaliplatin in the treatment of advanced gastric cancer. Methods: Totally 84 patients with advanced gastric cancer who failed in the first-line fluorouracil-based chemotherapy were enrolled. Randomly divided into observation group and control group, each group was 42 cases. The observation group was given Fufangping injection combined with docetaxel + oxaliplatin chemotherapy, the control group was given docetaxel + oxaliplatin chemotherapy alone, 21 days was a treatment cycle, continuous treatment of 2 to 6 cycle. The clinical efficacy, KPS score and adverse reactions of the two groups were observed. Results: The effective rates in observation group and control group were 35.00% and 14.63% respectively. The effective rate in observation group was significantly higher than that in control group (P <0.05). The disease control rate was 77.50%, which was higher than that in control group. The median PFS in observation group and control group were 6.3 months and 5.4 months respectively. The median PFS in observation group was significantly higher than that in control group (P <0.05). The median OS in observation group was 9.6 months, Higher than the control group. The improvement rate of KPS in observation group was 57.50%, which was significantly higher than that in control group (P <0.05). The incidence of neutropenia, leukopenia, thrombocytopenia and nausea and vomiting in observation group was significantly lower than that in control group (P <0.05). Conclusion: Xiaokaoping injection combined with docetaxel + oxaliplatin chemotherapy for advanced gastric cancer patients can significantly improve clinical efficacy, prolong survival, improve quality of life of patients and reduce chemotherapy-induced side effects, so that patients Clinical benefit.